Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity
Tingting Cui, Siyi Liu, Tingting Wang, Yarui Liu, Xinyue Liang, Faming Chen, Mingzhu Huang, Xiaoling Su, Tao Song, Jie Su, Shidong Deng, Jincun Zhao, Fulong Yu, Zhongfang Wang · 2025
Read Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity by Tingting Cui, Siyi Liu, Tingting Wang, Yarui Liu, Xinyue Liang, Faming Chen, Mingzhu Huang, Xiaoling Su, Tao Song, Jie Su, Shidong Deng, Jincun Zhao, Fulong Yu, Zhongfang Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751559.txt.
Description
Tingting Cui and co-authors study a Covid booster in 2025 using real infections with the BA.5 variant. Most vaccine proof comes from lab measures rather than natural exposure, so the team followed people through an actual wave. They compare a booster built on a modified cold virus against three doses of an inactivated vaccine.
The boosted group had about forty-eight percent protection against illness with symptoms, against ten percent for the other group. Deep immune profiling showed broader and stronger virus-blocking antibodies after the boost. Killer immune cells and antibody-guided attack also played a part. The study ties the real-world edge to this blend of defenses.
Catalog record
| CREATOR | Tingting Cui, Siyi Liu, Tingting Wang, Yarui Liu, Xinyue Liang, Faming Chen, Mingzhu Huang, Xiaoling Su, Tao Song, Jie Su, Shidong Deng, Jincun Zhao, Fulong Yu, Zhongfang Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |